In Section C, individuals will get ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disease progression or the participants are not able to tolerate the study drugs. 88 These preclinical studies provide paradigms for upcoming clinical trials in AML, https://abbv-744brd4inhibitioninc78013.izrablog.com/32489109/detailed-notes-on-abbv-744-brd4-inhibitor-mechanism-of-action